The Cardiopoiesis Platform

The Cardiopoiesis Platform

While most organs (such as the skin and bone) have a greater or lesser capacity for self-repair of damage, the heart does not have this capacity: it does not harbour large quantities of cardiac stem cells (CSCs) it can use for self-repair and the CSCs that are present in the heart are in a dormant state. Fundamental research at Mayo Clinic uncovered the mechanisms in the embryo that make an embryonic stem cell become a heart cell. This led to the identification of a 'Cardiopoietic cocktail' of proteins signalling the transformation of generic adult stem cells from other tissues into cardiac progenitor cells. The Cardiopoiesis platform aims to replicate the normal processes of cardiac development in the embryo, without attempting to permanently or temporarily modify the genome of the cell. As such, the platform recapitulates what nature does, while at the same time turning on every patient's reparative potential. The platform is also highly versatile and could be applied to various stem cell sources. The fundamental developmental biology knowledge of Cardiopoiesis has also allowed the addition of other programmes using allogeneic stem cells as well as protein-based research programmes. As such, Cardio3 BioSciences' pipeline includes multiple research programmes and product candidates seeking to address the high unmet medical needs in HF and AMI.